DO-2, an advanced MET kinase inhibitor, has finished enrollment in a Phase 1 trial. It displayed tumor shrinkage in all MET exon 14 skip NSCLC patients (with no other oncogenic drivers) at doses meeting preclinical criteria. The drug has shown promising results with a 100% tumor response rate in this group.